↓ Skip to main content

Targeting Sonic Hedgehog-Associated Medulloblastoma through Inhibition of Aurora and Polo-like Kinases

Overview of attention for article published in Cancer Research, October 2013
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
7 news outlets
blogs
1 blog
twitter
2 X users

Citations

dimensions_citation
54 Dimensions

Readers on

mendeley
89 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Targeting Sonic Hedgehog-Associated Medulloblastoma through Inhibition of Aurora and Polo-like Kinases
Published in
Cancer Research, October 2013
DOI 10.1158/0008-5472.can-12-4258
Pubmed ID
Authors

Shirley L. Markant, Lourdes Adriana Esparza, Jesse Sun, Kelly L. Barton, Lisa M. McCoig, Gerald A. Grant, John R. Crawford, Michael L. Levy, Paul A. Northcott, David Shih, Marc Remke, Michael D. Taylor, Robert J. Wechsler-Reya

Abstract

Medulloblastoma is the most common malignant brain tumor in children. Although aggressive surgery, radiation, and chemotherapy have improved outcomes, survivors suffer severe long-term side effects, and many patients still succumb to their disease. For patients whose tumors are driven by mutations in the sonic hedgehog (SHH) pathway, SHH antagonists offer some hope. However, many SHH-associated medulloblastomas do not respond to these drugs, and those that do may develop resistance. Therefore, more effective treatment strategies are needed for both SHH and non-SHH-associated medulloblastoma. One such strategy involves targeting the cells that are critical for maintaining tumor growth, known as tumor-propagating cells (TPC). We previously identified a population of TPCs in tumors from patched mutant mice, a model for SHH-dependent medulloblastoma. These cells express the surface antigen CD15/SSEA-1 and have elevated levels of genes associated with the G2-M phases of the cell cycle. Here, we show that CD15(+) cells progress more rapidly through the cell cycle than CD15(-) cells and contain an increased proportion of cells in G2-M, suggesting that they might be vulnerable to inhibitors of this phase. Indeed, exposure of tumor cells to inhibitors of Aurora kinase (Aurk) and Polo-like kinases (Plk), key regulators of G2-M, induces cell-cycle arrest, apoptosis, and enhanced sensitivity to conventional chemotherapy. Moreover, treatment of tumor-bearing mice with these agents significantly inhibits tumor progression. Importantly, cells from human patient-derived medulloblastoma xenografts are also sensitive to Aurk and Plk inhibitors. Our findings suggest that targeting G2-M regulators may represent a novel approach for treatment of human medulloblastoma.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 2 2%
Netherlands 1 1%
Italy 1 1%
United States 1 1%
Unknown 84 94%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 23 26%
Researcher 19 21%
Student > Bachelor 14 16%
Student > Master 8 9%
Student > Doctoral Student 7 8%
Other 9 10%
Unknown 9 10%
Readers by discipline Count As %
Agricultural and Biological Sciences 34 38%
Medicine and Dentistry 17 19%
Biochemistry, Genetics and Molecular Biology 11 12%
Pharmacology, Toxicology and Pharmaceutical Science 4 4%
Neuroscience 4 4%
Other 8 9%
Unknown 11 12%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 57. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 May 2014.
All research outputs
#631,811
of 22,723,682 outputs
Outputs from Cancer Research
#402
of 17,856 outputs
Outputs of similar age
#5,993
of 210,683 outputs
Outputs of similar age from Cancer Research
#2
of 138 outputs
Altmetric has tracked 22,723,682 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 17,856 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,683 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 138 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.